Sei Investments Co. Acquires 163,925 Shares of Brainsway Ltd. Sponsored ADR $BWAY

Key Points

• Sei Investments increased its Brainsway stake by 262.5% in the first quarter, purchasing 163,925 additional shares for a total of 226,378 shares valued at approximately $3.0 million. Institutional investors collectively own 30.11% of BWAY.
• Brainsway reported quarterly EPS of $0.12, beating the $0.05 consensus estimate, while revenue of $15.53 million exceeded expectations of $14.63 million. Analysts expect full-year EPS of $0.33.
• Analyst sentiment remains positive, with a consensus “Buy” rating and a $15.67 price target; BWAY recently opened at $15.50, near its 52-week high of $17.35.

Sei Investments Co. increased its holdings in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report) by 262.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 226,378 shares of the company's stock after purchasing an additional 163,925 shares during the period. Sei Investments Co. owned approximately 0.57% of Brainsway worth $3,009,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in BWAY. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Brainsway in the 1st quarter valued at approximately $40,000. Raymond James Financial Inc. acquired a new position in shares of Brainsway during the second quarter worth approximately $85,000. Bank of America Corp DE bought a new stake in shares of Brainsway in the third quarter valued at approximately $107,000. Royal Bank of Canada boosted its position in shares of Brainsway by 1,145.9% in the fourth quarter. Royal Bank of Canada now owns 8,410 shares of the company's stock valued at $160,000 after acquiring an additional 7,735 shares during the period. Finally, Centiva Capital LP acquired a new stake in shares of Brainsway in the third quarter worth $181,000. Institutional investors own 30.11% of the company's stock.

Brainsway Price Performance

BWAY opened at $15.50 on Friday. Brainsway Ltd. Sponsored ADR has a fifty-two week low of $5.84 and a fifty-two week high of $17.35. The firm's fifty day moving average price is $15.03 and its two-hundred day moving average price is $14.22. The company has a market capitalization of $622.01 million, a P/E ratio of 44.29 and a beta of 1.24.

Brainsway (NASDAQ:BWAY - Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.07. The firm had revenue of $15.53 million for the quarter, compared to analyst estimates of $14.63 million. Brainsway had a net margin of 15.68% and a return on equity of 12.28%. On average, equities research analysts expect that Brainsway Ltd. Sponsored ADR will post 0.33 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on BWAY. HC Wainwright reiterated a "buy" rating and set a $14.00 target price on shares of Brainsway in a research note on Friday, July 17th. Zacks Research upgraded shares of Brainsway from a "hold" rating to a "strong-buy" rating in a report on Monday, July 13th. BTIG Research initiated coverage on shares of Brainsway in a research report on Monday, July 20th. They set a "buy" rating and a $18.00 price objective for the company. Wall Street Zen upgraded shares of Brainsway from a "hold" rating to a "buy" rating in a research note on Sunday, August 2nd. Finally, New Street Research reissued a "buy" rating on shares of Brainsway in a research report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $15.67.

Brainsway Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway's technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company's flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.

Want to see what other hedge funds are holding BWAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source